Biophytis (EPA:ALBPS) | WebDisclosure

REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 7 months 15 days ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. La société publie ses résultats opérationnels et financiers pour l’exercice clos le 31 décembre 2023, mettant en avant ses avancées dans le développement de traitements pour les maladies liées à l'âge

Résultats Financiers Biophytis Développement Clinique Maladies Liées À L'âge Traitements
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 7 months 15 days ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 7 months 15 days ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA pour traiter l'obésité avec BIO101 (20-hydroxyecdysone), visant à préserver la masse musculaire. Programme ayant des résultats prometteurs, début de l'étude prévu mi-2024

Biophytis Étude Clinique BIO101 Obésité OBA
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 7 months 15 days ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
BRIEF

published on 04/08/2024 at 23:09, 7 months 15 days ago

Biophytis announces its 2023 financial results and provides an update on its activities

Biophytis Funding Clinical Development 2023 Financial Results BIO101
BRIEF

published on 04/08/2024 at 23:09, 7 months 15 days ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités

Biophytis Financement Développement Clinique Résultats Financiers 2023 BIO101
BRIEF

published on 04/08/2024 at 23:05, 7 months 15 days ago

Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 OBA Phase 2 Clinical Study GLP-1 Receptor Agonists
BRIEF

published on 04/08/2024 at 23:05, 7 months 15 days ago

Biophytis annonce une étude clinique de phase 2 sur le traitement de l'obésité avec BIO101

Biophytis BIO101 Étude Clinique De Phase 2 OBA Traitement De L'obésité Agonistes Des Récepteurs GLP-1
PRESS RELEASE

published on 04/08/2024 at 23:04, 7 months 15 days ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023

Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE

published on 04/08/2024 at 23:04, 7 months 15 days ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial

Published on 11/22/2024 at 23:55, 1 day 5 hours ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 5 hours ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 5 hours ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 1 day 5 hours ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 6 hours ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 1 day 10 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 1 day 10 hours ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 1 day 11 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 12 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 day 12 hours ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 17:45, 1 day 11 hours ago

IMMERSION : RFA 2023/2024
Published on 11/22/2024 at 16:15, 1 day 12 hours ago

NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/22/2024 at 14:35, 1 day 14 hours ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 1 day 14 hours ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 21 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio

View all LES ECHOS COMFI WIRE

News